BCL2L11 and prostate carcinoma: Furthermore, it was reported that CDC20 overexpression facilitates the docetaxel resistance of the castration-resistant prostate cancer (CRPC) cell lines in a Bim-dependent manner, indicating that the drugs targeting CDC20 were urgent to be developed for the treatment of the CRPC with docetaxel resistance (Wu et al., 2018).